Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by El-Mowafy, A. M.
Right arrow Articles by Alkhalaf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Mowafy, A. M.
Right arrow Articles by Alkhalaf, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 24, No. 5, 869-873, May 2003
© 2003 Oxford University Press

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism

Abdalla M. El-Mowafy1,3 and Moussa Alkhalaf2

1 Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, PO Box 24923, Safat 13110, Kuwait
2 Department of Biochemistry, Faculty of Medicine, Health Sciences Center, Kuwait University, PO Box 24923, Safat 13110, Kuwait

3 To whom correspondence should be addressed Email: aelmowafy{at}hsc.kuniv.edu.kw

Resveratrol (RSVL) is a well-established chemopreventive agent in human breast cancer models. The molecular basis of its action is far less characterized. We investigated the effects of RSVL on activity of adenylate- and guanylate-cyclase (AC, GC) enzymes; two known cytostatic cascades in MCF-7 breast cancer cells. RSVL increased cAMP levels in both time- and concentration-dependent manners (t1/2, 6.2 min; EC50 0.8 µM). In contrast, it had no effect on cGMP levels. The stimulatory effects for RSVL on AC were not altered either by the protein synthesis inhibitor (actinomycin-D, 5 µM) or the estrogen-receptor (ER) blockers (tamoxifen and ICI182,780, 1 µM each). Likewise, cAMP formation by RSVL was insensitive to either the broad-spectrum phosphodiesterase (PDE) inhibitor (IBMX, 0.5 mM) or the cAMP-specific PDE inhibitor (rolipram, 10 µM). Instead, these PDE inhibitors significantly augmented maximal cAMP formation by RSVL. Parallel experiments showed that either RSVL or rolipram inhibited the proliferation of these cells in a concentration-responsive manner. Further, concurrent treatment with RSVL and rolipram significantly enhanced their individual cytotoxic responses. The antiproliferative effects were appreciably reversed by the kinase-A inhibitors, Rp-cAMPS (100–300 µM) or KT-5720 (10 µM). Pretreatment with the cPLA2 inhibitor arachidonyl trifluoromethyl ketone (10 µM) markedly antagonized the cytotoxic effects of RSVL, but had no effect on that of rolipram. Altogether, the present study demonstrates, for the first time, that the chemotherapeutic agent RSVL is an agonist for the cAMP/kinase-A system, a documented pro-apoptic and cell-cycle suppressor in breast cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
K. A. Seely, M. S. Levi, and P. L. Prather
The Dietary Polyphenols trans-Resveratrol and Curcumin Selectively Bind Human CB1 Cannabinoid Receptors with Nanomolar Affinities and Function as Antagonists/Inverse Agonists
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 31 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Y. Li, P. Hao, S. Zheng, K. Tu, H. Fan, R. Zhu, G. Ding, C. Dong, C. Wang, X. Li, et al.
Gene expression module-based chemical function similarity search
Nucleic Acids Res., November 1, 2008; 36(20): e137 - e137.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. Burstein, A. Maguy, R. Clement, H. Gosselin, F. Poulin, N. Ethier, J.-C. Tardif, T. E. Hebert, A. Calderone, and S. Nattel
Effects of Resveratrol (trans-3,5,4'-Trihydroxystilbene) Treatment on Cardiac Remodeling following Myocardial Infarction
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 916 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. Szkudelski
Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances
Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E901 - E907.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Blumenstein, B. Keseru, F. Wolter, and J. Stein
The Chemopreventive Agent Resveratrol Stimulates Cyclic AMP-Dependent Chloride Secretion In vitro
Clin. Cancer Res., August 1, 2005; 11(15): 5651 - 5656.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. E. Donnelly, R. Newton, G. E. Kennedy, P. S. Fenwick, R. H. F. Leung, K. Ito, R. E. K. Russell, and P. J. Barnes
Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms
Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L774 - L783.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.